Genetic Testing in Medullary Thyroid Carcinoma
|
|
- Austen Burke
- 6 years ago
- Views:
Transcription
1 Genetic Testing in Medullary Thyroid Carcinoma Presenter-Dr Sunil Malla Bujar Barua Moderator- Prof Gaurav Agarwal 1 Genetic testing in MTC 24/4/2012
2 Background 1959 Hazard et al first described MTC 1961 John Sipple recognized the association between thyroid cancer & pheochromocytoma 1965 Schimke & Hartman described syndrome of pheochromocytoma & MTC with amyloid stroma 1968 Steiner and colleagues described the association between MTC, pheochromocytoma, and hyperparathyroidism as multiple endocrine neoplasia (MEN), type Matthew Simpson MEN 2A putative locus 10p12 p11 10q Mulligan, Donis-Keller Identification of MEN2 gene (RET) in MEN 2/FMTC families Specific RET Proto-oncogene mutations 2 Genetic testing in MTC 24/4/2012
3 Medullary Thyroid Cancer MTC represents approximately 4% of all thyroid cancers. Sporadic 75% of cases (non-inherited, presenting typically in the fourth decade as a unifocal lesion without associated endocrinopathy. Inherited 25% of cases 95% of MEN2A and MEN 2B cases have germline mutations 88% of familial MTC cases have germline mutations 25% (up to 50%) of sporadic MTC cases have somatic mutations
4 RET RET is an abbreviation for "rearranged during transfection" DNA sequence originally found to be rearranged within a 3T3 fibroblast cell line following its transfection with DNA taken from human lymphoma cells 4 Genetic testing in MTC 24/4/2012
5 RET protein Is a trans cell membrane receptor with a extracellular and an intracellular portion. Transmits signals for growth depending upon stimulation by growth factors which attach to the extracellular portion of receptor Has activating and deactivating mutations Plays role in development of - Intestinal neurons -Autonomic nervous system -Normal kidney development -Spermatogenesis 5 Genetic testing in MTC 24/4/2012
6 Crystallographic structure dimeric tyrosine kinase domain of the human Ret proto-oncogene (Nterminus = blue, C- terminus= red). Knowles PP et al. J. Biol. Chem. 281 (44): Genetic testing in MTC 24/4/2012
7 Components of the RET Signaling Pathway Co-receptors: GFR 1, 2, 3, & 4 Growth Factor Ligands: GDNF, NRTN, ARTN, PSPN
8 Cys GDNF GFR 1 Cys Cys Cys Extracellular Domain Cell Membrane P P Intracellular Domain RAS-RAF Pathway PI3 Kinase Pathway
9 FMTC/MEN2-associated Mutations in the RET Proto-oncogene Cadherin-like domain Codon mutated Exon MEN2 phenotype Frequency of mutation in MEN2A/FMTC or MEN2B Cysteine-rich domain Transmembrane region FMTC/MEN2A 611 FMTC/MEN2A 618 FMTC/MEN2A 23 % 620 MEN2A/FMTC FMTC 634 MEN2A/FMTC 66 % Tyrosine kinase 1 Tyrosine kinase FMTC 1% 790 MEN2A/FMTC 791 MEN2A/FMTC 8 % 804 FMTC 1% FMTC 1% MEN2B 3% 891 FMTC 1% MEN2B 95% 9 Genetic testing in MTC 24/4/2012
10 The Effects of Mutations on RET Function Ligand independent dimerization, activation, and transformation. Constitutive Phosphorylation of intracellular proteins. Overactive Signaling
11 Cys GFR 1 Cys Cys Arg Extracellular Domain Cell Membrane P P P P Intracellular Domain Over Active Signalling to Cells Uncontrolled Cell Proliferation
12 Polymerase Chain Reaction 12 Genetic testing in MTC 24/4/2012
13 Discovery PCR discovery widely credited to Kary Mullis-1983 On a long motorcycle drive Mentally visualized the process Nobel Prize in Chemistry 1993
14 Properties of DNA polymearse Needs a pre-existing DNA to duplicate Cannot assemble a new strand from components Called template DNA Can only extend an existing piece of DNA Called primers
15
16
17
18
19 Properties of DNA polymearse DNA polymerase needs Mg ++ as cofactor Each DNA polymerase works best under optimal temperature, ph and salt concentration PCR buffer provides optimal ph and salt condition
20 Properties of DNA polymearse DNA strands are anti-parallel One strand goes in 5 3 The complementary strand is opposite DNA polymerase always moves in one direction (from 5 3 )
21 Properties of DNA polymearse DNA polymerase incorporates the four nucleotides (A, T, G, C) to the growing chain dntp follow standard base pairing rule datp datp datp datp datp dgtp dttp dgtp dctp dttp dctp 5 dttp dttp dctp 3 dgtp datp dctp 3 5 dttp datp dctp dttp dgtp dgtp dctp dgtp
22 Properties of DNA polymearse The newly generated DNA strands serve as template DNA for the next cycle PCR is very sensitive
23 Setting up a PCR Reaction Add template DNA and primers Add dntps Add DNA polymerase dttp datp datp datp datp datp dgtp dttp dgtp dctp dctp 5 dttp dttp dctp 3 dgtp datp dctp 3 5 dttp datp dctp dttp dgtp dgtp dctp dgtp
24 Taq DNA polymerase Derived from Thermus aquaticus Heat stable DNA polymerase Ideal temperature 72C
25 Thermal Cycling A PCR machine controls temperature Typical PCR go through three steps Denaturation Annealing Extension
26 Denaturation Heating separates the double stranded DNA Denaturation Slow cooling anneals the two strands Renaturation Heat Cool
27 Annealing Two primers are supplied in molar excess They bind to the complementary region As the DNA cools, they wedge between two template strands Optimal temperature varies based on primer length etc. Typical temperature from 40 to 60 C
28 Extension DNA polymerase duplicates DNA Optimal temperature 72C
29 PCR Amplification Exponential Amplification of template DNA
30 Typical PCR mix In a thin wall Eppendorf tube assemble the following PCR components Template DNA (5-200 ng) 1 mm dntps (200 um final) 10 X PCR buffer 25 mm MgCl2 (1.5 mm final) 20 um forward primer (20 pmoles final) 20 um reverse primer (20 pmoles final) 5 units/ul Taq DNA polymerase (1.5 units) Water Final Volume Amount variable 10 ul 5 ul 3 ul 1 ul 1 ul 0.3 ul Variable 50 ul
31 What is genetic counseling? Process through which individuals affected by or at risk for a problem which may be genetic or hereditary, are informed of Consequences of disorder Probablity of suffering and transmission to offspring Means of treating or avoiding occurrence of malformation or disease
32 Key Issues with genetic testing Can we claim confidentiality over our genetic information? What personal consequences does genetic information have? What implications does it have on family members? Who should have access to the information? Employers? Insurance companies? Government? Meet the Gene Machine
33 Genetic Counselor Health care professional with a master degree in human genetics and counseling. In common disorders- family doctor, pediatrician or pediatrician
34 Pretest Genetic counseling Implications should be discussed with family members Genetic transmission, probability of inheritance Risk and benefits Potential of genetic discrimination in employment Life and health insurance Privacy issues Potential in genetic testing errors Potentials of future technologies prenatal testing Therapy Role of life long surveillance Psychological and social support mechanisms should be available Written consent Post test counseling 34 Genetic testing in MTC 24/4/2012
35 Why Screen? 25% of all MTCs are Familial* Up to 7% of persons with apparently sporadic MTC or pheochromocytoma have RET proto-oncogene mutation* May follow diffuse hyperplasia nodular hyperplasia medullary thyroid carcinoma sequence At the stage of palpable nodule- tumor is nearly 1 cm and 50% may have metastasis in neck nodes** *Elisei etal. J Clin Endocrinol Metab (12): **Leboulleux etal. Clin Endocrinol 2004; 61: Genetic testing in MTC 24/4/2012
36 Why Screen? The aim of screening depends on the phenotypic expression MTC - for prophylactic intervention PCC - for early detection and appropriate management HPT - for early detection and appropriate management 36 Genetic testing in MTC 24/4/2012
37 Whom to screen? Asymptomatic 1 st degree relatives of a RET mutation carrier proband Relatives expressing one or the other components. Two Methods Testing for all RET exons 10,11,13,14,15,16. Focused testing for known RET mutation in the proband Brandi etal. J Clin Endocrinol Metab 2001;86(12): Genetic testing in MTC 24/4/2012
38 How to screen? Genetic Screening RET mutation analysis 38 Genetic testing in MTC 24/4/2012
39 Genetic screening vs Calcitonin Genetic Testing: Once in a life time Easy to perform Prophylactic Thyroidectomy possible Early detection before biochemical postivity Spared the expense & inconvenience of repeated testing Both prenatal & preimplantation testing available Detect 95% of pts with MEN 2A, MEN 2B & 88% with FMTC False positive rate <1% Basal/Stimulated Calcitonin : Positive test indicates Cancer has already developed Provocative tests Unpleasant & uncomfortable Annual tesing Assess the burden of disease Important in monitoring for residual/recurrent disease after Thyx False positive rate 5-10% Learoyd et al, Arch Surg 1997;132: /4/2012 Machens et al, Genetic World J testing Surg 2007;31: in MTC 39
40 Codon specific Age related MTC progression in familial syndromes Codon 609,611,618,620,630,63 4(n=165) 768,791,804,891(n=27) CCHP Mean Age Node ve MTC Node +ve MTC P value < = *918(n=17) (n=129) <0.001 *Codon 918,611, 791 no stastical difference 609,630,891- No or scarce data hence needs further verification Study 1- n=207 age<20,t<1.0cm Study 2 n=167 Machens etal. N Engl J Med 2003; 349: *Machens etal. Surgery 2003;134: /4/2012 Genetic testing in MTC 40
41 RET Mutations RET mutation correlates with the phenotypic expression of MEN 2 Pheo & HPT : M.C with Codon 634 mutations HPT : does not occur in codon 918 mutation M.C mutation : mis-sense mutation at codon 634 in change from cysteine to arginine RET mutations stratified into 3 groups on the aggressiveness of MTC Codon 609, 768, 790, 791, 804 & 891 Codon 611, 618, 620 & 634 Codon 883 & 918 Yip L et al, Arch Surg 2003; 138: Genetic testing in MTC 24/4/2012
42 Age of Manifestation Codon Age of MTC Age of Lymph node Mets Highest Risk 883,918,922 Age of distant metastasis < 1yr 2.5 yrs 5 yrs High Risk 611,618,620,634 <1yr (634) <5 yrs (rest) 1 st and 2 nd Decade 3 rd Decade Low Risk 609,768,790,804,891 2 nd to 3 rd decade 2nd to 4 th decade >4 th Decade Machens etal. World J Surg 2007;31: Genetic testing in MTC 24/4/2012
43 Prophylactic Thyroidectomy Risk Highest risk (Level 3) High risk (Level 2) Least aggressive (Level 1) Solution TT+ CCLND within 6 months of age preferably within 1 month TT +/- CCLND before 5 yrs of age Between 5-10yrs TT Brandi etal. J Clin Endocrinol Metab, 2001;86(12) Genetic testing in MTC 24/4/2012
44 ATA Risk Level & Prophylactic Thyroidectomy testing & Therapy ATA risk level D (918,883) C (634) Age of RET testing ASAP & within 1 st yr of life Age of required first USG ASAP & within 1 st yr of life Age of required first serum Ct 6 months, if surgery not already done Age of Prophylactic Thyx ASAP & within the 1 st yr of life <3-5 yrs >3-5 yrs >3-5 yrs Before age 5 yrs B (620,630, 609, 611,618) A (804,790, 791 ) <3-5 yrs >3-5 yrs >3-5 yrs Consider Surgery before age 5. May delay surgery beyond 5 yrs of age if stringent criteria are met <3-5 Yrs >3-5 yrs >3-5 yrs May delay Surgery beyond age 5 yrs if stringent criteria are met Stringent Criteria : normal annual basal+/- stimulated serum Ct, normal neck USG, less aggressive MTC family history, & family preference ASAP = as soon as possible Kloos TR et al, Management Guidelines of the ATA, Thyroid;19:6,2009 : Genetic testing in MTC 24/4/2012
45 Current Recommendation for screening All Cases of apparently sporadic MTC should be tested for germline mutation Mutations involving RET exons 10,11,13,14,15 and 16 should be tested routinely If these are negative then test for additional 15 Exons Exons 13,14 & 15 should be screened carefully as they have low incidence of PCC hence prone for missing the syndromic association Screening in kindred can be for the specific codon mutation detected in Proband Tests in tumour tissue for somatic RET mutation in sporadic MTC or in sporadic PCC are generally not recommended for clinical use Brandi etal. J Clin Endocrinol Metab, 2001;86(12) Genetic testing in MTC 24/4/2012
46 Current Recommendation for screening Basal or stimulated calcitonin immuno-assays is used to monitor tumour status for recurrence / persistence / or metastasis. RET testing should be considered for <50 yrs onset and bilateral PCC Periodic screening for tumours in MEN 2 carrier is based upon the MEN 2 variant, as characterized by the codon mutation and by manifestations in the rest of the family members Brandi etal. J Clin Endocrinol Metab, 2001;86(12) Genetic testing in MTC 24/4/2012
47 47 Genetic testing in MTC 24/4/2012
48 Clinical implications of RET mutations 48 Machens A et al, NEJM 2003,349: Genetic testing in MTC 24/4/2012
49 Genetic testing in diagnosis and management of MEN Patient with MTC (Index case) Germline RET mutation analysis RET +ve patient (hereditary disease) RET mutation analysis in all first degree relatives Ret ve patient / Not done Pentagastrin test in 3 first degree relatives RET negative RET positive Negative pentagastrin test-insignificant risk No further evaluation Surgery Positive Surgery For those refusing surgery / subjects with exon 13,14,15 mutations Pentagastrin test Negative Annual pentagastrin test 49 Genetic testing in MTC 24/4/2012
50 Summary RET mutation testing should be done for all sporadic cases of Medullary thyroid carcinoma Genetic Screening is a reliable test for detection of at risk individuals and will help to avoid further screening of not at risk kindreds(50%) Timing of Surgery may be different depending on the risk categorization of the codon mutations Timing for Screening of associated components of MEN 2 differs with different codon mutations due to the variation in association. Genetic Counseling is an essential part of managing these patients 50 Genetic testing in MTC 24/4/2012
A KINDRED WITH a RET CODON Y791F MUTATION PRESENTING WITH HIRSCHSPRUNG S S DISEASE.
A KINDRED WITH a RET CODON Y791F MUTATION PRESENTING WITH HIRSCHSPRUNG S S DISEASE. ד"ר מרב פרנ קל ד גנית ברק גרוס דיויד פרופסור השרות לאנדוקרינ ולוגיה ומטבוליזם ירושלים ה דסה עין כר םם, Case Report 36
More informationCarcinoma midollare tiroideo familiare
12 AME Italian Meeting 6 Joint Meeting with AACE Carcinoma midollare tiroideo familiare Profilo genetico e stratificazione del rischio Maria Chiara Zatelli Sezione di Endocrinologia Dipartimento di Scienze
More informationThe c-ret pathway and. K. Homicsko, Lucerne
The c-ret pathway and biomarkers K. Homicsko, 2.11.12 Lucerne Origins 1. c-ret is a proto-oncogene on chromosome 10 (10q11.2) 2. «rearranged during transfection» 3. Synonyms: CDHF12, HSCR1, MEN2A, MEN2B,
More informationATA Guidelines for Medullary Thyroid Cancer: approach to initial management of sporadic and inherited disease
ATA Guidelines for Medullary Thyroid Cancer: approach to initial management of sporadic and inherited disease Richard T. Kloos, M.D. The Ohio State University Divisions of Endocrinology and Nuclear Medicine
More informationCalcitonin. 1
Calcitonin Medullary thyroid carcinoma (MTC) is characterized by a high concentration of serum calcitonin. Routine measurement of serum calcitonin concentration has been advocated for detection of MTC
More informationTiming of Early Preventative Thyroidectomy in Children with MEN 2
Timing of Early Preventative Thyroidectomy in Children with MEN 2 Terry C. Lairmore, M.D. Professor of Surgery Director, Division of Surgical Oncology Texas Chapter of AACE Texas Endocrine Surgical Symposium
More informationTransgenic Mice and Genetargeting
Transgenic Mice and Genetargeting mice In Biomedical Science Techniques of transgenic and gene-targeting mice are indispensable for analyses of in vivo functions of particular genes and roles of their
More informationGenetics and Genomics in Endocrinology
Genetics and Genomics in Endocrinology Dr. Peter Igaz MD MSc PhD 2 nd Department of Medicine Faculty of Medicine Semmelweis University Genetics-based endocrine diseases I. Monogenic diseases: Multiple
More informationResult Navigator. Positive Test Result: RET. After a positive test result, there can be many questions about what to do next. Navigate Your Results
Result Navigator Positive Test Result: RET Positive test results identify a change, or misspelling, of DNA that is known or predicted to cause an increased risk for cancer. DNA is the blueprint of life
More informationMedullary Thyroid Cancer. Caroline S. Kim, MD Perelman School of Medicine at the University of Pennsylvania February 13, 2016
Medullary Thyroid Cancer Caroline S. Kim, MD Perelman School of Medicine at the University of Pennsylvania February 13, 2016 I have no disclosures 30 minutes on Medullary Thyroid Cancer (MTC) Classification
More informationRossella Elisei. Department of Endocrinology, University Hospital, Pisa, Italy
Rossella Elisei Department of Endocrinology, University Hospital, Pisa, Italy THYROID CANCER IS RARE TUMOR AND REPRESENTS ONLY 3.8% OF ALL HUMAN TUMORS All human cancer Thyroid cancer MOST FREQUENT CANCER
More informationMedullary thyroid carcinoma: surgical treatment advances Gianlorenzo Dionigi a, Maria Laura Tanda b and Eliana Piantanida b
Medullary thyroid carcinoma: surgical treatment advances Gianlorenzo Dionigi a, Maria Laura Tanda b and Eliana Piantanida b a Department of Surgical Sciences and b Clinical Medicine, University of Insubria,
More information5/1/2010. Genetic testing in patients with endocrine tumors. Genetic testing in Patients with Endocrine Tumors
Genetic testing in patients with endocrine tumors Why? Jessica E. Gosnell MD Assistant Prof of Surgery April 30, 2010 Genetic testing in Patients with Tumors Indications & Interpretation Germline mutations
More informationClinical significance of RET mutation screening in a pedigree of multiple endocrine neoplasia type 2A
MOLECULAR MEDICINE REPORTS 14: 1413-1417, 2016 Clinical significance of RET mutation screening in a pedigree of multiple endocrine neoplasia type 2A RONGBIAO YING and JUN FENG Department of Surgical Oncology,
More informationMedullary Thyroid Cancer: Medullary Thyroid Cancer
Review & Update Nothing to disclose. Jessica E. Gosnell MD Assistant Professor in Residence Department of Surgery November 9, 2012 Medullary Thyroid Cancer MTC has distinct embryology, genetic association
More informationProphylactic Thyroidectomy in Multiple Endocrine Neoplasia Type 2A
original article Prophylactic Thyroidectomy in Multiple Endocrine Neoplasia Type 2A Michael A. Skinner, M.D., Jeffrey A. Moley, M.D., William G. Dilley, Ph.D., Kouros Owzar, Ph.D., Mary K. DeBenedetti,
More informationInitial Lymph Node Dissection Increases Cure Rates in Patients with Medullary Thyroid Cancer
Original Article Initial Lymph Node Dissection Increases Cure Rates in Patients with Medullary Thyroid Cancer David Yü Greenblatt, Diane Elson, 1 Eberhard Mack and Herbert Chen, Departments of Surgery
More informationFailure to Recognize Multiple Endocrine Neoplasia 2B: More Common Than We Think?
Annals of Surgical Oncology 15(1):293 301 DOI: 10.1245/s10434-007-9665-4 Failure to Recognize Multiple Endocrine Neoplasia 2B: More Common Than We Think? Curtis J. Wray, 1 Thereasa A. Rich, 1 Steven G.
More informationTHYROID CANCER IN CHILDREN. Humberto Lugo-Vicente MD FACS FAAP Professor Pediatric Surgery UPR School of Medicine
THYROID CANCER IN CHILDREN Humberto Lugo-Vicente MD FACS FAAP Professor Pediatric Surgery UPR School of Medicine Thyroid nodules Rare Female predominance 4-fold as likely to be malignant Hx Radiation exposure?
More informationDr Catherine Woolnough, Hospital Scientist, Chemical Pathology, Royal Prince Alfred Hospital. NSW Health Pathology University of Sydney
Dr Catherine Woolnough, Hospital Scientist, Chemical Pathology, Royal Prince Alfred Hospital NSW Health Pathology University of Sydney Thyroid Cancer TC incidence rates in NSW Several subtypes - Papillary
More informationAACE/ACE Disease State Clinical Review
AACE/ACE Disease State Clinical Review Terry C. Lairmore, MD, FACS 1 ; Diana Diesen, MD 2 ; Melanie Goldfarb, MD, FACS 3 ; Mira Milas, MD, FACS 4 ; Anita K. Ying, MD 5 ; Jyotirmay Sharma, MD, FACS 6 ;
More informationCabozantinib for medullary thyroid cancer. February 2012
Cabozantinib for medullary thyroid cancer February 2012 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive
More informationMEDULLARY thyroid carcinoma (MTC) may arise as
0021-972X/97/$03.00/0 Vol. 82, No. 10 Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright 1997 by The Endocrine Society A Case of Metastatic Medullary Thyroid Carcinoma: Early
More informationChasing the ubiquitous RET proto-oncogene in South African MEN2 families implications for the surgeon
Chasing the ubiquitous RET proto-oncogene in South African MEN2 families implications for the surgeon S. W. MOORE, M.B. CH.B., F.R.C.S. (EDIN.), M.D. Division of Paediatric Surgery, Department of Surgical
More information- RET/PTC rearrangement: 20% papillary thyroid cancer - RET: medullary thyroid cancer
Thyroid Cancer UpToDate: Introduction: Risk Factors: Biology: Symptoms: Diagnosis: 1. Lenvina is the first line therapy with powerful durable response and superior PFS in pts with RAI-refractory disease.
More informationMTC and MEN2: Past, Present, and Future
MTC and MEN2: Past, Present, and Future Steven G. Waguespack, MD, FACE Professor Dept. of Endocrine Neoplasia and Hormonal Disorders Department of Pediatrics-Patient Care University of Texas M.D. Anderson
More informationNational Horizon Scanning Centre. Vandetanib (Zactima) for locally advanced or metastatic medullary thyroid cancer. December 2007
Vandetanib (Zactima) for locally advanced or metastatic medullary thyroid cancer December 2007 This technology summary is based on information available at the time of research and a limited literature
More informationB. Environmental Factors. a. The major risk factor to papillary thyroid cancer is exposure to ionizing radiation, during the first 2 decades of life.
B. Environmental Factors. a. The major risk factor to papillary thyroid cancer is exposure to ionizing radiation, during the first 2 decades of life. b. Deficiency of dietary iodine: - Is linked with a
More informationMultiple endocrine neoplasia type 2B in a Chinese patient. Citation Hong Kong Medical Journal, 2004, v. 10 n. 3, p
Title Multiple endocrine neoplasia type 2B in a Chinese patient Author(s) Chang, A; Chan, WF; Lo, CY; Lam, KSL Citation Hong Kong Medical Journal, 2004, v. 10 n. 3, p. 206-209 Issued Date 2004 URL http://hdl.handle.net/10722/45152
More informationGenetic Testing of Inherited Cancer Predisposition Genetic Testing - Oncology
Genetic Testing of Inherited Cancer Predisposition Genetic Testing - Oncology Policy Number: Original Effective Date: MM.02.010 05/01/2010 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration
More informationA 93-year-old MEN2A mutation carrier without Medullary Thyroid Carcinoma: a case report and overview of the literature
A 93-year-old mutation carrier without Medullary Thyroid Carcinoma: a case report and overview of the literature Karin van der Tuin 1, Nandy Hofland 1, Natasha M. Appelman-Dijkstra 2, Rob B. van der Luijt
More informationPEDIATRIC Ariel Katz MD
PEDIATRIC Ariel Katz MD Dept. Otolaryngology Head &Neck Surgery Wolfson Medical Center Holon, Israel OBJECTIVES Overview/Background Epidemiology/Etiology Intro to Guidelines Workup Treatment Follow-Up
More information2. Multiple Endocrine Neoplasia Type 2
2. Multiple Endocrine Neoplasia Type 2 Mimi I. Hu, MD Robert F. Gagel, MD Introduction Multiple endocrine neoplasia type 2 (MEN-2) is a rare, autosomal dominant inherited syndrome characterized by medullary
More informationWhat is Thyroid Cancer?
Thyroid Cancer What is Thyroid Cancer? The thyroid is a gland at the base of the throat near the trachea (windpipe). It is shaped like a butterfly, with a right lobe and a left lobe. The isthmus, a thin
More informationTHE IMPACT OF FAMILY HISTORY ON MEDULLARY THYROID CANCER IN MEN2A PATIENTS
Texas Medical Center Library DigitalCommons@TMC UT GSBS Dissertations and Theses (Open Access) Graduate School of Biomedical Sciences 5-2013 THE IMPACT OF FAMILY HISTORY ON MEDULLARY THYROID CANCER IN
More informationChapter 1 Current concepts in RET-related genetics and signalling
Chapter 1 Current concepts in RET-related genetics and signalling Ivan Plaza-Menacho 1, Grzegorz M. Burzynski 1, Bart J. L. Eggen 2, Robert M. W. Hofstra 1 Department of Medical Genetics 1, University
More information11/29/2017. Genetics and Cancer ERICA L SILVER, MS, LCGC GENETIC COUNSELOR. Genetics 101. Transcription vs Translation
Genetics and Cancer ERICA L SILVER, MS, LCGC GENETIC COUNSELOR Genetics 101 Transcription vs Translation 1 Carcinogenesis and Genetics Normal cell First mutation First mutation Second mutation Second mutation
More informationMEDULLARY THYROID CANCER and RELATED MEN SYNDROMES. Irina Kovatch, MD SUNY Downstate Medical Center Grand Rounds January 26 th, 2012
MEDULLARY THYROID CANCER and RELATED MEN SYNDROMES Irina Kovatch, MD SUNY Downstate Medical Center Grand Rounds January 26 th, 2012 Thyroid Cancer Comprises 95% of all endocrine malignancies and 1.5% of
More informationCase Report Simultaneous medullary thyroid carcinoma and pheochromocytoma: a case report of MEN2A
Int J Clin Exp Med 2016;9(6):12269-12274 www.ijcem.com /ISSN:1940-5901/IJCEM0021871 Case Report Simultaneous medullary thyroid carcinoma and pheochromocytoma: a case report of MEN2A Lei Zhao, Cheng Yang,
More information3/29/2012. Thyroid cancer- what s new. Thyroid Cancer. Thyroid cancer is now the most rapidly increasing cancer in women
Thyroid cancer- what s new Thyroid Cancer Changing epidemiology Molecular markers Lymph node dissection Technical advances rhtsh Genetic testing and prophylactic surgery Vandetanib What s new? Jessica
More informationDiagnostic Challenges in Multiple Endocrine Neoplasia Type 1 (MEN1) : Usefulness of Genetic Analysis
Diagnostic Challenges in Multiple Endocrine Neoplasia Type 1 (MEN1) : Usefulness of Genetic Analysis Professor R. V. Thakker, FRS May Professor of Medicine University of Oxford, U.K. Meet The Experts 49
More informationThyroid Nodules. Family Medicine Refresher Course Geeta Lal MD, FACS April 2, No financial disclosures
Thyroid Nodules Family Medicine Refresher Course Geeta Lal MD, FACS April 2, 2014 No financial disclosures Objectives Review epidemiology Work up of Thyroid nodules Indications for FNAB Evolving role of
More informationUltrasound-Guided Fine-Needle Aspiration of Thyroid Nodules: New events
Ultrasound-Guided Fine-Needle Aspiration of Thyroid Nodules: New events Sandrine Rorive, M.D., PhD. Erasme Hospital - Université Libre de Bruxelles (ULB) INTRODUCTION The assessment of thyroid nodules
More informationParaganglioma & Pheochromocytoma Syndromes: Genetic Risk Assessment
Paraganglioma & Pheochromocytoma Syndromes: Genetic Risk Assessment 60 th Annual Spring Symposium for Houston Society of Clinical Pathologists Houston, TX April 6 th, 2019 Samuel Hyde, MMSc, CGC Certified
More informationPolicy Specific Section: Medical Necessity and Investigational / Experimental. October 14, 1998 March 28, 2014
Medical Policy Genetic Testing for Colorectal Cancer Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Laboratory/Pathology Original Policy Date: Effective Date: October
More informationPersistent & Recurrent Differentiated Thyroid Cancer
Persistent & Recurrent Differentiated Thyroid Cancer Electron Kebebew University of California, San Francisco Department of Surgery Objectives Risk factors for persistent & recurrent disease Causes of
More informationInformation for You and Your Family
Information for You and Your Family What is Prevention? Cancer prevention is action taken to lower the chance of getting cancer. In 2017, more than 1.6 million people will be diagnosed with cancer in the
More informationIntroduction to Genetics
Introduction to Genetics Table of contents Chromosome DNA Protein synthesis Mutation Genetic disorder Relationship between genes and cancer Genetic testing Technical concern 2 All living organisms consist
More informationAn Overview of Molecular Abnormalities. A 1993 Perspective. Leading to Thyroid Carcinogenesis: ROBERT F. GAGEL ABSTRACT
An Overview of Molecular Abnormalities Leading to Thyroid Carcinogenesis: A 1993 Perspective ROBERT F. GAGEL University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA Key Words. Medullary thyroid
More informationAccepted 6 December 2012 Published online 6 March 2013 in Wiley Online Library (wileyonlinelibrary.com). DOI /hed.23241
CASE REPORT Jonathan Irish, MD, FRCSC, Section Editor Novel tandem germline RET proto-oncogene mutations in a patient with multiple endocrine neoplasia type 2B: Report of a case and a literature review
More informationShifrin et al Surgery Volume 148, Number 6
Single nucleotide polymorphisms act as modifiers and correlate with the development of medullary and simultaneous medullary/papillary thyroid carcinomas in 2 large, non-related families with the RET V804M
More informationWTC 2013 Panel Discussion: Minimal disease
WTC 2013 Panel Discussion: Minimal disease Susan J. Mandel MD MPH Panelists Ken Ain Yasuhiro Ito Stephanie Lee Erich Sturgis Mark Urken Faculty/Presenter Disclosure Relationships with commercial interests
More informationAllinaHealthSystems 1
Overview Biology and Introduction to the Genetics of Cancer Denise Jones, MS, CGC Certified Genetic Counselor Virginia Piper Cancer Service Line I. Our understanding of cancer the historical perspective
More informationAcute: Symptoms that start and worsen quickly but do not last over a long period of time.
Cancer Glossary Acute: Symptoms that start and worsen quickly but do not last over a long period of time. Adjuvant therapy: Treatment given after the main treatment. It usually refers to chemotherapy,
More informationGoiter, Nodules and Tumors
Goiter, Nodules and Tumors Howard J. Sachs, MD www.12daysinmarch.com Thyroid Cancer Anaplastic Medullary Thyroid Cancer Anaplastic Medullary Thyroid Cancer Anaplastic Medullary Anaplastic Medullary MEN
More informationWhat causes cancer? Physical factors (radiation, ionization) Chemical factors (carcinogens) Biological factors (virus, bacteria, parasite)
Oncogenes What causes cancer? Chemical factors (carcinogens) Physical factors (radiation, ionization) Biological factors (virus, bacteria, parasite) DNA Mutation or damage Oncogenes Tumor suppressor genes
More informationCitation for published version (APA): Verbeek, H. (2015). Medullary Thyroid Carcinoma: from diagnosis to treatment [S.l.]: [S.n.]
University of Groningen Medullary Thyroid Carcinoma Verbeek, Hans IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document
More informationRole of Paired Box9 (PAX9) (rs ) and Muscle Segment Homeobox1 (MSX1) (581C>T) Gene Polymorphisms in Tooth Agenesis
EC Dental Science Special Issue - 2017 Role of Paired Box9 (PAX9) (rs2073245) and Muscle Segment Homeobox1 (MSX1) (581C>T) Gene Polymorphisms in Tooth Agenesis Research Article Dr. Sonam Sethi 1, Dr. Anmol
More informationPromising New Treatments for Metastatic Differentiated and Medullary Thyroid Cancer. Marcia Brose MD PhD
Promising New Treatments for Metastatic Differentiated and Medullary Thyroid Cancer Marcia Brose MD PhD Department of Otorhinolaryngology: Head and Neck Surgery Department of Medicine, Division of Hematology/Oncology
More informationInsulin Resistance. Biol 405 Molecular Medicine
Insulin Resistance Biol 405 Molecular Medicine Insulin resistance: a subnormal biological response to insulin. Defects of either insulin secretion or insulin action can cause diabetes mellitus. Insulin-dependent
More informationTYROSINE KINASES ARE involved in the most essential
0163-769X/06/$20.00/0 Endocrine Reviews 27(5):535 560 Printed in U.S.A. Copyright 2006 by The Endocrine Society doi: 10.1210/er.2006-0017 RET as a Diagnostic and Therapeutic Target in Sporadic and Hereditary
More informationDepartment of Endocrine Neoplasia and Hormonal Disorders. Medical Management of Medullary Thyroid Carcinoma
ENDOPERSPECTIVES Department of Endocrine Neoplasia and Hormonal Disorders N E W S L E T T E R Volume 1, Issue 2 Medical Management of Medullary Thyroid Carcinoma Mimi I. Hu, M.D., Assistant Professor Department
More informationHeide Siggelkow, Ariane Melzer, Wilhelm Nolte, Klara Karsten, Wolfgang HoÈppner 1 and Michael HuÈ fner
European Journal of Endocrinology (2001) 144 467±473 ISSN 0804-4643 CLINICAL STUDY Presentation of a kindred with familial medullary thyroid carcinoma and Cys611Phe mutation of the RET proto-oncogene demonstrating
More informationoncogenes-and- tumour-suppressor-genes)
Special topics in tumor biochemistry oncogenes-and- tumour-suppressor-genes) Speaker: Prof. Jiunn-Jye Chuu E-Mail: jjchuu@mail.stust.edu.tw Genetic Basis of Cancer Cancer-causing mutations Disease of aging
More informationGerard M. Doherty, MD
Surgical Management of Differentiated Thyroid Cancer: Update on 2015 ATA Guidelines Gerard M. Doherty, MD Chair of Surgery Utley Professor of Surgery and Medicine Boston University Surgeon-in-Chief Boston
More information2015 American Thyroid Association Thyroid Nodule and Cancer Guidelines
2015 American Thyroid Association Thyroid Nodule and Cancer Guidelines Angela M. Leung, MD, MSc, ECNU November 5, 2016 Outline Workup of nontoxic thyroid nodule(s) Ultrasound FNAB Management of FNAB results
More informationCorporate Medical Policy
Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer
More informationMedullary Thyroid Carcinoma: New Therapies and Trials
Medullary Thyroid Carcinoma: New Therapies and Trials Matthew D. Ringel, MD Ralph W. Kurtz Chair and Professor of Medicine Director, Division of Endocrinology, Diabetes, and Metabolism The Ohio State University
More informationCitation for published version (APA): Verbeek, H. (2015). Medullary Thyroid Carcinoma: from diagnosis to treatment [S.l.]: [S.n.]
University of Groningen Medullary Thyroid Carcinoma Verbeek, Hans IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document
More informationInitial surgery for differentiated thyroid cancer: What is the appropriate extent and attendant risks and benefits?
Initial surgery for differentiated thyroid cancer: What is the appropriate extent and attendant risks and benefits? Julie Ann Sosa, MD MA FACS Professor of Surgery and Medicine Chief, Section of Endocrine
More informationGenetics of Cancer Lecture 32 Cancer II. Prof. Bevin Engelward, MIT Biological Engineering Department
Genetics of Cancer Lecture 32 Cancer II rof. Bevin Engelward, MIT Biological Engineering Department Why Cancer Matters New Cancer Cases in 1997 Cancer Deaths in 1997 Genetics of Cancer: Today: What types
More informationGENETIC TESTING FOR TARGETED THERAPY FOR NON-SMALL CELL LUNG CANCER (NSCLC)
CANCER (NSCLC) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are
More informationRET Gene Mutations (Genotype and Phenotype) of Multiple Endocrine Neoplasia Type 2 and Familial Medullary Thyroid Carcinoma
Review Article RET Gene Mutations (Genotype and Phenotype) of Multiple Endocrine Neoplasia Type 2 and Familial Medullary Thyroid Carcinoma Geoffrey W. Krampitz, MD; and Jeffrey A. Norton, MD The rapid
More informationEndocrine Surgery. Characteristics of the Germline MEN1 Mutations in Korea: A Literature Review ORIGINAL ARTICLE. The Korean Journal of INTRODUCTION
ORIGINAL ARTICLE ISSN 1598-1703 (Print) ISSN 2287-6782 (Online) Korean J Endocrine Surg 2014;14:7-11 The Korean Journal of Endocrine Surgery Characteristics of the Germline MEN1 Mutations in Korea: A Literature
More informationThyroid Cancer: When to Treat? MEGAN R. HAYMART, MD
Thyroid Cancer: When to Treat? MEGAN R. HAYMART, MD ASSOCIATE PROFESSOR OF MEDICINE UNIVERSITY OF MICHIGAN MICHIGAN AACE 2018 ANNUAL MEETING Thyroid Cancer: When Not to Treat? FOCUS WILL BE ON LOW-RISK
More informationcolorectal cancer Colorectal cancer hereditary sporadic Familial 1/12/2018
colorectal cancer Adenocarcinoma of the colon and rectum is the third most common site of new cancer cases and deaths in men (following prostate and lung or bronchus cancer) and women (following breast
More informationCurrent concepts in RET-related genetics, signaling and therapeutics
Review TRENDS in Genetics Vol.22 No.11 Current concepts in RET-related genetics, signaling and therapeutics Ivan Plaza-Menacho 1,2*, Grzegorz M. Burzynski 1*, Jan Willem de Groot 3, Bart J.L. Eggen 4 and
More informationDiseases of the breast (2 of 2) Breast cancer
Diseases of the breast (2 of 2) Breast cancer Epidemiology & etiology The most common type of cancer & the 2 nd most common cause of cancer death in women 1 of 8 women in USA Affects 7% of women Peak at
More informationAPPROCCIO DIAGNOSTICO-TERAPEUTICO TERAPEUTICO AL CARCINOMA DIFFERENZIATO DELLA TIROIDE Sabato 6 aprile 2013 Aula Magna Nuovo Arcispedale S.
dal 1846 APPROCCIO DIAGNOSTICO-TERAPEUTICO TERAPEUTICO AL CARCINOMA DIFFERENZIATO DELLA TIROIDE Sabato 6 aprile 2013 Aula Magna Nuovo Arcispedale S. Anna Ruolo dell analisi genetica Maria Chiara Zatelli
More informationAre you at risk of Hereditary Cancer? Your Guide to the Answers
Are you at risk of Hereditary Cancer? Your Guide to the Answers What is Hereditary Cancer? The genes we are born with may contribute to our risk of developing certain types of cancer, including breast,
More informationTumor suppressor genes D R. S H O S S E I N I - A S L
Tumor suppressor genes 1 D R. S H O S S E I N I - A S L What is a Tumor Suppressor Gene? 2 A tumor suppressor gene is a type of cancer gene that is created by loss-of function mutations. In contrast to
More informationGENETIC TESTING: WHAT DOES IT REALLY TELL YOU? Shawnia Ryan, MS, LCGC Senior Genetic Counselor University of New Mexico Cancer Center
GENETIC TESTING: WHAT DOES IT REALLY TELL YOU? Shawnia Ryan, MS, LCGC Senior Genetic Counselor University of New Mexico Cancer Center What is genetic counseling? communication process address individual
More informationCase year old female presented with asymmetric enlargement of the left lobe of the thyroid
Case 4 22 year old female presented with asymmetric enlargement of the left lobe of the thyroid gland. No information available relative to a prior fine needle aspiration biopsy. A left lobectomy was performed.
More informationCase 4 Diagnosis 2/21/2011 TGB
Case 4 22 year old female presented with asymmetric enlargement of the left lobe of the thyroid gland. No information available relative to a prior fine needle aspiration biopsy. A left lobectomy was performed.
More information4/22/2010. Hakan Korkmaz, MD Assoc. Prof. of Otolaryngology Ankara Dıșkapı Training Hospital-Turkey.
Management of Differentiated Thyroid Cancer: Head Neck Surgeon Perspective Hakan Korkmaz, MD Assoc. Prof. of Otolaryngology Ankara Dıșkapı Training Hospital-Turkey Thyroid gland Small endocrine gland:
More informationA large Chinese pedigree of multiple endocrine neoplasia type 2A with a novel C634Y/D707E germline mutation in RET exon 11
3552 A large Chinese pedigree of multiple endocrine neoplasia type 2A with a novel C634Y/D707E germline mutation in RET exon 11 FANQIAN LU 1,2, XIAOHONG CHEN 1,2, YUNLONG BAI 1,2, YARU FENG 1,2 and JIAN
More informationThe power of bacterial genetics is the potential for studying rare events
The types of experiments that a geneticist can do are dictated to a great extent by the model organism that s/he is working with The power of bacterial genetics is the potential for studying rare events
More informationActivation of cellular proto-oncogenes to oncogenes. How was active Ras identified?
Dominant Acting Oncogenes Eugene E. Marcantonio, M.D. Ph.D. Oncogenes are altered forms of normal cellular genes called proto-oncogenes that are involved in pathways regulating cell growth, differentiation,
More informationSupplementary Tables. Supplementary Figures
Supplementary Files for Zehir, Benayed et al. Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients Supplementary Tables Supplementary Table 1: Sample
More informationCancer genetics
Cancer genetics General information about tumorogenesis. Cancer induced by viruses. The role of somatic mutations in cancer production. Oncogenes and Tumor Suppressor Genes (TSG). Hereditary cancer. 1
More informationCase Report Nonfunctional Metastatic Parathyroid Carcinoma in the Setting of Multiple Endocrine Neoplasia Type 2A Syndrome
Surgery Research and Practice, Article ID 731481, 4 pages http://dx.doi.org/10.1155/2014/731481 Case Report Nonfunctional Metastatic Parathyroid Carcinoma in the Setting of Multiple Endocrine Neoplasia
More informationA descriptive study on solitary nodular goitre
Original Research Article A descriptive study on solitary nodular goitre T. Chitra 1*, Dorai D. 1, Aarthy G. 2 1 Associate Professor, 2 Post Graduate Department of General Surgery, Govt. Stanley Medical
More informationMegan R. Haymart, MD 83 rd Annual Meeting of the ATA October 16, 2013
Megan R. Haymart, MD 83 rd Annual Meeting of the ATA October 16, 2013 Disclosure: Nothing to Disclose Learning Objectives Thyroid cancer - diagnosis - prognosis - treatment - follow-up Thyroid function
More informationRisk Adapted Follow-Up
Risk Adapted Follow-Up Individualizing Follow- Up Strategies R Michael Tuttle, MD Clinical Director, Endocrinology Service Memorial Sloan Kettering Cancer Center Professor of Medicine Weill Medical College
More informationHistopathologic and Clinical Features of Medullary Microcarcinoma and C-Cell Hyperplasia in Prophylactic Thyroidectomies for Medullary Carcinoma
Histopathologic and Clinical Features of Medullary Microcarcinoma and C-Cell Hyperplasia in Prophylactic Thyroidectomies for Medullary Carcinoma A Study of 42 Cases Demet Etit, MD; William C. Faquin, MD,
More informationYES. If yes, indicate what types of tumors/polyps and age of onset:
REQUEST FOR FAMILIAL ADENOMATOUS POLYPOSIS (FAP) TESTING Please provide the following information. We cannot perform your test without ALL of this information. PLEASE PRINT ALL ANSWERS PATIENT INFORMATION
More informationPrevalence and clinical implications of BRCA1/2 germline mutations in Chinese women with breast cancer Yuntao Xie M.D., Ph.D.
Prevalence and clinical implications of BRCA1/2 germline mutations in Chinese women with breast cancer Yuntao Xie M.D., Ph.D. Hereditary Cancer Center, Peking University Cancer Hospital 1 Breast cancer
More informationTable S1. Primers and PCR protocols for mutation screening of MN1, NF2, KREMEN1 and ZNRF3.
Table S1. Primers and PCR protocols for mutation screening of MN1, NF2, KREMEN1 and ZNRF3. MN1 (Accession No. NM_002430) MN1-1514F 5 -GGCTGTCATGCCCTATTGAT Exon 1 MN1-1882R 5 -CTGGTGGGGATGATGACTTC Exon
More informationSALSA MLPA probemix P169-C2 HIRSCHSPRUNG-1 Lot C As compared to version C1 (lot C1-0612), the length of one probe has been adjusted.
mix P169-C2 HIRSCHSPRUNG-1 Lot C2-0915. As compared to version C1 (lot C1-0612), the length of one has been adjusted. Hirschsprung disease (HSCR), or aganglionic megacolon, is a congenital disorder characterised
More information